CA-SENTRY
Sentry, the leader in developer-first application monitoring, today announced it has acquired Codecov, the leading dedicated code coverage reporting solution, providing developers with actionable insights into their workflow. The acquisition expands Sentry’s product offering for development teams to improve code quality and velocity even earlier in the development life cycle, helping to accelerate remediation and enabling the delivery of better end-user experiences.
“Our mission has always been to empower developers to ship high quality code, faster than anyone else through context and insights, versus dashboards and tools that frankly weren’t built for resolution,” said Milin Desai, CEO of Sentry. “The Codecov team shares this singular focus – and enables us to offer developers even more comprehensive insight into their application’s code quality earlier in the development cycle.”
Codecov is the leading dedicated code coverage solution, which helps thousands of development teams at companies like Lyft, Slack, Washington Post, GoodRx, and Alteryx, confidently ship stable code. Similar to Sentry, Codecov works within developers’ existing workflows for software development, providing feedback, insight, and ownership over the quality of code regardless of platform, language, or CI/CD tooling. With the acquisition, Sentry customers will benefit from insights and protection over their code quality both pre- and post-deployment.
"At Lyft, we want to help our developers reliably ship code as fast as possible by providing an environment that allows them to feel confident to make and ship changes in code," said Jun Li, Staff Software Engineer at Lyft. "Codecov provides a source of truth for our teams. It reduces friction as it is flexible enough to fit into any language and CI/CD so engineers can see the impact and dig deeper into code changes, all in one place. The implementation of Codecov has improved the overall developer experience and we're seeing more and more adoption of it across our teams.”
“From day one, our primary focus has been on using tools like code coverage to help developers ship quickly and reliably,” said Jerrod Engelberg, CEO of Codecov. “There’s an obvious alignment between Sentry and Codecov in how we empower developers to feel confident in making and shipping changes. We are climbing the same summit of software reliability from opposite sides, and with this, our customers new and old will experience faster development cycles, quicker discovery and remediation of bugs, and an overall better developer experience. ”
Codecov providing intelligent code coverage furthers Sentry’s commitment to addressing the evolving needs of software developers who are using tooling that is not purpose-built for their workflows or their most pressing problems. The addition of Codecov, along with Sentry’s other recent investments will serve to evolve application monitoring for software developers everywhere.
Codecov’s talented and experienced team, including co-founders Jerrod Engelberg and Eli Hooten, will join the Sentry team.
Read the Sentry and Codecov blogs to learn more about how the companies will work together to bring a new level of actionable insight directly into the developer’s workflow.
About Sentry
For software teams, Sentry is essential for monitoring application code quality. From Error tracking to Performance monitoring, developers can see clearer, solve quicker, and learn continuously about their applications — from frontend to backend. Loved by more than 3.5 million developers and 85,000 organizations worldwide, Sentry provides code-level observability to many of the world’s best-known companies like Disney, Cloudflare, Eventbrite, Slack, Supercell, and Rockstar Games. Learn more at sentry.io or follow Sentry on GitHub, Twitter, Dribbble, or LinkedIn.
About Codecov
Codecov is the leading dedicated code coverage reporting solution focused on helping developers quickly ship reliable code while helping engineering teams save time and improve the overall developer experience. The company helps thousands of development teams at some of the world’s largest companies like Lyft, Slack, Washington Post, GoodRx, and Alteryx, confidently deliver stable and bug-free code with highly integrated tools to surface coverage insights where they are needed.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129006193/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
